# Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

> **NCT05679024** · PHASE3 · RECRUITING · sponsor: **Region Stockholm** · enrollment: 1400 (estimated)

## Conditions studied

- Chronic Kidney Diseases
- Atrial Fibrillation
- Stroke
- Intracerebral Hemorrhage
- Major Bleed
- Cardiovascular Complication
- Death
- Kidney Transplant; Complications
- Thromboses, Venous

## Interventions

- **DRUG:** Apixaban 2.5 milligram Oral Tablet

## Key facts

- **NCT ID:** NCT05679024
- **Lead sponsor:** Region Stockholm
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05679024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05679024, "Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05679024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*